[WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers].
We assessed the efficacy of WT1 class I peptide and WT1 class II peptide pulsed dendritic cell(DC)therapy for a wide range of advanced cancers. This retrospective study included 60 advanced cancer patients who were vaccinated 5times or more in this clinic between September 2013 and December 2015. The clinical response was examined. This treatment was approved by the ethics panel at this institution. Sixty patients were injected an average of 6.15times with dendritic cells(DCs) (2.6×10 / 7 cells/injection). Overall, 55of 60(92%)patients achieved a clinical benefit per the RECIST v1.1 criteria. The median survival time(MST)from diagnosis was 26.9 months, and the MST from the first admission at this institution was 12.2 months. Complete response(CR)was achieved in 5patients(9.1%), partial response(PR)in 12(22%), and stable disease(SD) in 21(38%), with confirmed progressive disease(PD)in 17(31%). In 11 cases of pancreatic cancer, the response(RR)and disease control rates(DCR)were 27%and 55%,respectively. In 8 cases of colorectal cancer, the rates were 25% and 75%; in 7 cases of lung cancer, the rates were 29% and 43%; in 7 cases of gastric cancer, the rates were 71% and 86%; in 22 other types, the rates were 23% and 74%. These results demonstrated the potential clinical efficacy of DC-based immunotherapy.